Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785001 | Advances in Radiation Oncology | 2017 | 5 Pages |
Abstract
Our findings suggest that heart dose may be a surrogate for other prognostic factors in stage III NSCLC rather than an independent predictor of outcome.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Laura K. MD, Stephen R. PhD, Olga PhD, Matthew J. PhD, Shilpen A. MD, Jing MD, Ramesh MD, PhD,